Glenn Hammonds

First post: Feb 27, 2019 Latest post: May 2, 2021
I was diagnosed with intrahepatic cholangiocarcinoma, also known as bile duct cancer, in January 2019. The historical survival 5 years after diagnosis has been 1 in 10, a rather dismal prognosis. Thankfully, I have benefited from excellent care including partial hepatectomy (75% of liver was removed), radiation for bone metastasis and two different chemotherapies for liver metastases. In November of 2019, I was enrolled in a clinical trial of an  FGFR inhibitor. FGFR2  is the driver mutation identified by genomic analysis. After more than 336 days on the oral FGFR inhibitor my liver metastases resumed growth due to blocking mutations so a new direction was taken.  After installation of an infusion port and a surgical procedure to clear the bile duct chemotherapy (FOLFOX) started 2/2/21 in anticipation of a clinical trial of a newFGFR2 specific inhibitor. starting perhaps by April.  **Note bene** Feb 3 update was lost in while editing. I will post some picture and restore the update  later noting.